Skip to Main Content

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


Bristol-Myers Squibb: Win some, lose some. Just a few days after disclosing it will not seek accelerated approval for a combination of its Opdivo and Yervoy immunotherapies, the drug maker will get $625 million from Merck. Why? Bristol-Myers and its Opdivo partner, Ono Pharmaceutical, claimed Merck’s Keytruda infringed on their own PD-1 patents underpinning their drug. Merck will also pay royalties on global Keytruda sales over the next decade. This is not going to compensate for concerns that Bristol-Myers is falling behind Merck in immunotherapies, but it’s better than nothing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!